Related Experiment Video
Updated: Jun 28, 2026
08:19
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Vasculitis induced by tumor necrosis factor-targeted therapies
Manuel Ramos-Casals1, Pilar Brito-Zerón, Maria-Jose Cuadrado
1Servei de Malalties Autoimmunes, Hospital Clínic, C/Villarroel, 170, 08036-Barcelona, Spain. mramos@clinic.ub.es
Current Rheumatology Reports
|November 15, 2008
Summary
Tumor necrosis factor (TNF)-targeted therapies can trigger new autoimmune conditions like vasculitis. This review analyzes 132 cases of vasculitis that developed after anti-TNF treatment, examining clinical features and outcomes.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Tumor necrosis factor (TNF)-targeted therapies are widely used for rheumatic and autoimmune diseases.
- Increased use and longer follow-up reveal emerging autoimmune processes linked to these therapies.
Purpose of the Study:
- To analyze clinical characteristics, outcomes, and associations of vasculitis developing after TNF-targeted therapy.
- To review all reported cases of vasculitis post-anti-TNF treatment.
Main Methods:
- Systematic review of reported cases of vasculitis.
- Analysis of clinical data, treatment, and outcomes for 132 patients.
- Categorization based on specific anti-TNF agents used.
Main Results:
- A total of 132 cases of vasculitis post-anti-TNF therapy were identified up to July 2008.
- The review details the clinical presentations and outcomes associated with these cases.
- Patterns of association between specific anti-TNF agents and vasculitis development are examined.
Conclusions:
- TNF-targeted therapies are associated with the development of vasculitis.
- Understanding these associations is crucial for managing patients on anti-TNF treatments.
- Further research is needed to elucidate the mechanisms and optimize treatment strategies.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cytotoxic Edema: Pathophysiology
Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...